// added the section below on July 01 2024 // till here on July 01 2024

Progressive Supranuclear Palsy Market

Progressive Supranuclear Palsy (PSP) Therapies Market by Type of Treatment (Curative and Palliative / Symptomatic), and Key Geographical Regions (US, UK, Germany, France, Italy and Spain): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 4,799

  • Pages

  • View Count

Progressive Supranuclear Palsy Market Overview

The Progressive Supranuclear Palsy (PSP) therapies market is estimated to be worth around $77 million in 2024 and is expected to grow at compounded annual growth rate (CAGR) of 36% during the forecast period. The “Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Progressive Supranuclear Palsy.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Progressive Supranuclear Palsy, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2021-2031.

This image highlights the context of Progressive Supranuclear Palsy Market report. Despite extensive ongoing R&D efforts on understanding the etiopathology of Progressive Supranuclear Palsy (PSP), no drug has received approval for the treatment of this rare and complex neurodegenerative disorder, till date This image provides list of Progressive Supranuclear Palsy Drugs. The pipeline for Progressive Supranuclear Palsy features both biologics and small molecule drugs, which are being evaluated for their therapeutic potential in clinical and pre-clinical stages This image describes pipeline review of Progressive Supranuclear Palsy. Majority of the candidates are in clinical development; primarily, these are small molecules designed to target the aggregates of insoluble tau protein, a histological hallmark of PSP

Recent Developments in Progressive Supranuclear Palsy (PSP) Therapies Market:

Several recent developments have taken place in the field of Progressive Supranuclear Palsy (PSP) Therapies. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In July 2023, Amylyx Pharmaceuticals hosted virtual webcast on AMX0035 Progressive Supranuclear Palsy (PSP) program. 
  • In February 2023, Ferrer acquired worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, with an aim to strengthen its portfolio focusing for the treatment of Progressive Supranuclear Palsy (PSP). 
  • In February 2023, ASN90 received orphan drug designations from EMA and the US FDA for the treatment of progressive supranuclear palsy.

Scope of the Report

  • A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and mechanism of action across the complete product development cycle, including all clinical and nonclinical stages.
  • Detailed profiles of the players that are engaged in the development of drug products / therapies for Progressive Supranuclear Palsy, featuring overview of the company, its financial information (if available), a description of its product portfolio, recent collaborations and an informed future outlook.
  • An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population, route of administration, treatment type and dosing frequency, and target patient population, expected launch date and size of developer company.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
  • An analysis of the partnerships that have been established in the domain, over the last five years, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status, and trial focus, highlighting leading sponsors, type of organization, and regional distribution of trials. In addition, it features an insightful clinical end-points analysis.
This image highlights the geographical distribution of Progressive Supranuclear Palsy Developers. Organizations involved in the development of PSP therapies are primarily based in developed geographies; within North America, California and Massachusetts have emerged as the key hubs This image provides information about completed, ongoing and planned clinical studies of Progressive Supranuclear Palsy. More than 100 clinical trials, related to PSP, were registered in the last two decades; ~90% of these studies have either been completed or are currently recruiting patients This image provides information on grants that have been awarded to research institutes engaged in conducting projects related to Progressive Supranuclear Palsy. Several non-profit organizations have extended financial support to aid the research related to PSP; grants worth over USD 300 million, disbursed across 700+ instances, have been awarded since 2010

Key Questions Answered

  • What are the prevalent R&D trends related to Progressive Supranuclear Palsy?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the principal therapies developed by the companies in this domain?
  • Who are the leading industry and non-industry players in this market?
  • What are the contributions of big pharma players in this field?
  • What are the key geographies where research on Progressive Supranuclear Palsy is being conducted?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts in this field?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
This image highlights the analysis of identifying the key opinion leaders in the domain of Progressive Supranuclear Palsy. Several scientists, clinicians and industry veterans, affiliated to academic / medical / commercial organizations are spearheading research related to PSP; these KOLs are mostly based in US, France and Germany This image presents review of scientific articles related to Progressive Supranuclear Palsy Therapies. Since the first description of PSP in 1963, the attention to this rare disorder and potential treatments has intensified; this is evident from the volume of literature published since 2010 This image provides information on the current and future market trends and potential growth of Progressive Supranuclear Palsy Market. The market in 2024 is estimated to be worth USD 78 million; this value is projected to reach USD 492 million by 2030, growing at a CAGR of 36% between 2024-2030


This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com